about
Harnessing the immune system to improve cancer therapyDendritic cell-based vaccination in cancer: therapeutic implications emerging from murine modelsNovel targeted therapeutics for metastatic castration-resistant prostate cancer.AACR centennial series: the biology of cancer metastasis: historical perspectiveMelanoma genetics and the development of rational therapeutics.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaTreatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsMHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cellsAdjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Cytokine gene therapy for malignant glioma.Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.Enhanced metastasis in RNF13 knockout mice is mediated by a reduction in GM-CSF levels.Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.Adenovirus as vehicle for anticancer genetic immunotherapy.Current immunotherapeutic strategies for central nervous system tumors.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasImmune cell recruitment and cell-based system for cancer therapy.Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancerCharacterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Cytokines in cancer immunotherapy.Validation of analytical methods in compliance with good manufacturing practice: a practical approachA dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerFuture perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Velimogene aliplasmid.Amino acid metabolism related to immune tolerance by MDSCs.The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.Intralesional immunotherapy for melanoma.Treating advanced melanoma: current insights and opportunities.Immunotherapeutic approaches for cancer therapy: An updated review.Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.Novel oncolytic viral therapies in patients with thoracic malignancies.
P2860
Q26738698-DC884B9E-0CDF-41EF-9874-26BCC4D6C584Q27012618-7D36D105-D5EC-4C2C-A1C9-24BC8C528900Q33642278-CF914417-1E43-4897-A5EB-EA0720983172Q33683443-55E5C000-10C3-4733-8C83-DB8106497584Q33726956-2940C172-99AA-46C2-8080-DC5E8FCC7917Q33734281-1B0ECC09-D170-4DB2-BD07-5E0DDACE5FBAQ34111789-63BFBD94-922C-42B1-B191-53F83F48D23AQ34183436-08053E10-3353-4F89-84D2-9E7823FCDD7FQ35673240-4A380A53-F08A-4CE9-B43F-63B0983C6C4DQ35751117-B97F019E-9250-462D-95A1-F74C31F95D2CQ35886450-46BF7F31-8772-4DA7-B016-4B3839D221A6Q35907022-EC6229E9-7E17-4381-AA8B-DD48EA5A2D17Q35928330-E1086FAA-6ACF-45FF-8A5E-1120381D2FA2Q36137690-552F7EE0-C095-493B-B488-53E4185A79FAQ36262281-E9AD3225-04A6-412B-AE81-7C46514CB99FQ36288930-58E9F83F-5184-4655-A6D5-823214281035Q36325239-E6A14EA0-A9E3-443A-9867-A94FC353D239Q36478070-C92A70FE-6AEE-4A99-9490-31956D93FB6FQ36517706-219F221F-A57D-4026-90D1-DBC425F8EB19Q36597391-244D72DC-37C0-493B-8056-2063DD0248B5Q36625526-9E70481D-D499-4801-B71D-8EAB06954E9DQ36941194-85E3309D-4DDB-4BEB-8284-9FE3CB16218DQ37014134-08CABF4B-A724-460D-A664-6750BFB45913Q37148152-287C1107-E911-4AC2-9D12-F8A315C7F706Q37152649-223B9E18-FC95-4A48-8707-56978F2B0BCDQ37223381-F0075ECB-D371-4C17-A18C-0917438F9B34Q37365673-C67D6691-B755-40E7-B4B7-E7CA9E784A24Q37417271-DDBBB0F5-F078-47CC-BEBD-F18B849BBF71Q37635491-18A540EE-AEB2-4ABD-8420-2CBFED1C92A3Q37724340-D16E2892-9F95-4F0C-8D89-EB87B983F1E2Q38010200-6D0BE191-C533-492D-B31F-40AD9FCEFA84Q38161874-299883E5-E31A-4FF5-845C-131981DE4C3DQ38168460-AB95D553-3E73-4FC9-97A6-2802692C62E4Q38250316-1AE1B068-0031-423D-AE3C-F6D77502FD60Q38388102-72E95D8B-C696-4182-85CD-20151BC44F00Q38630561-59510E0D-FA59-422A-B09E-6F0F73698079Q38893420-1502A394-A3DA-4CEA-8F05-8C271D0060BBQ38936958-ECB42ED5-FA02-4044-97C1-9AE15E89CD9AQ39037485-0E18FB72-BD04-4C8E-AF2D-1BEF0ECCF5F6Q39067827-992B6D01-64FE-4D5D-8C4D-AC1AE2C1DEA7
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
GM-CSF-secreting melanoma vaccines.
@ast
GM-CSF-secreting melanoma vaccines.
@en
type
label
GM-CSF-secreting melanoma vaccines.
@ast
GM-CSF-secreting melanoma vaccines.
@en
prefLabel
GM-CSF-secreting melanoma vaccines.
@ast
GM-CSF-secreting melanoma vaccines.
@en
P2860
P356
P1433
P1476
GM-CSF-secreting melanoma vaccines.
@en
P2093
Glenn Dranoff
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206459
P407
P577
2003-05-01T00:00:00Z
P5875
P6179
1017146287